MicroRNA-381 inhibits cell proliferation and invasion in endometrial carcinoma by targeting the IGF-1R

  • Authors:
    • Chunhua Tu
    • Fen Wang
    • Junhui Wan
  • View Affiliations

  • Published online on: December 18, 2017     https://doi.org/10.3892/mmr.2017.8288
  • Pages: 4090-4098
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endometrial carcinoma (EC) is the sixth most common type of malignant tumor occurring in females. MicroRNAs (miRNAs) serve as oncogenes or tumor suppressors in human cancer and play important roles in tumorigenesis, and tumor development by regulating various processes. Thus, further investigation into miRNAs involved in EC formation and progression may aid in developing effective therapeutic strategies for patients with this disease. miRNA‑381 (miR‑381) is aberrantly expressed in multiple types of human cancer. However, the expression pattern, biological roles and underlying mechanisms of miR‑381 in EC are poorly understood. In the present study, the results showed that miR‑381 was downregulated in EC tissues and cell lines. Decreased miR‑381 expression correlated with the International Federation of Gynecology and Obstetrics stage, lymph nodes metastasis and myometrial invasion of EC. The ectopic expression of miR‑381 significantly inhibited the proliferation and invasion of EC cells. Through a series of experiments, the insulin‑like growth factor receptor 1 (IGF‑1R) was identified as a novel direct target of miR‑381 in EC. Furthermore, IGF‑1R was highly expressed in EC tissues and inversely correlated with miR‑381 levels. IGF‑1R overexpression partially abrogated the tumor‑suppressive effects of miR‑381 on the proliferation and invasion of EC cells. miR‑381 targeted IGF‑1R to inactivate the protein kinase B (AKT) and extracellular signal‑regulated kinase (ERK) signaling pathways in EC. These results suggest that miR‑381 acts as a tumor suppressor in EC by directly targeting IGF‑1R, and indirectly regulating the AKT and ERK signaling pathways. Thus, miR‑381 should be investigated as a prognostic biomarker and novel therapeutic target for the treatment of patients with EC.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Jin F, Devesa SS, Chow WH, Zheng W, Ji BT, Fraumeni JF Jr and Gao YT: Cancer incidence trends in urban Shanghai, 1972–1994: An update. Int J Cancer. 83:435–440. 1999. View Article : Google Scholar : PubMed/NCBI

3 

Dahlgren E, Friberg LG, Johansson S, Lindström B, Odén A, Samsioe G and Janson PO: Endometrial carcinoma; ovarian dysfunction-a risk factor in young women. Eur J Obstet Gynecol Reprod Biol. 41:143–150. 1991. View Article : Google Scholar : PubMed/NCBI

4 

Chen YL, Wang KL, Chen MY, Yu MH, Wu CH, Ke YM, Chen YJ, Chang YY, Hsu KF and Yen MS: Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: A retrospective observational study of Taiwanese Gynecologic Oncology Group. J Gynecol Oncol. 24:14–20. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas A, et al: p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med. 4:808–824. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Vale CL, Tierney J, Bull SJ and Symonds PR: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 15:CD0039152012.

7 

Boll D, Verhoeven RH, van der Aa MA, Pauwels P, Karim-Kos HE, Coebergh JW and van Doorn HC: Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989–2008. Int J Gynecol Cancer. 22:599–606. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI

9 

Moreno-Moya JM, Vilella F and Simoón C: MicroRNA: Key gene expression regulators. Fertil Steril. 101:1516–1523. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI

13 

Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Vandenboom Ii TG, Li Y, Philip PA and Sarkar FH: MicroRNA and cancer: Tiny molecules with major implications. Curr Genomics. 9:97–109. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 106:pp. 1814–1819. 2009; View Article : Google Scholar : PubMed/NCBI

16 

Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu P: microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. Oncol Lett. 7:1219–1224. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Liang C, Zhang X, Wang HM, Liu XM, Zhang XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis. 8:e27642017. View Article : Google Scholar : PubMed/NCBI

18 

Yang X, Ruan H, Hu X, Cao A and Song L: miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2. Am J Cancer Res. 7:913–922. 2017.PubMed/NCBI

19 

Xia B, Li H, Yang S, Liu T and Lou G: miR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Zhou S, Ye W, Ren J, Shao Q, Qi Y, Liang J and Zhang M: MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma. Am J Cancer Res. 5:267–277. 2014.PubMed/NCBI

21 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Shu S, Li X, Yang Y, Zhang Y, Li T, Liang C and Wan J: Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. Int Immunopharmacol. 11:244–249. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Pengchong H and Tao H: Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol. 32:660–664. 2011.PubMed/NCBI

24 

Chen G, Fang T, Huang Z, Qi Y, Du S, Di T, Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells proliferation and invasion via targeting IGF-1R. Cell Physiol Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Ding WZ, Ni QF, Lu YT, Kong LL, Yu JJ, Tan LW and Kong LB: MicroRNA-497 regulates cell proliferation in hepatocellular carcinoma. Oncol Lett. 11:1081–1088. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB and Moriwaki H: EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 262:10–18. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Hou XW, Sun X, Yu Y, Zhao HM, Yang ZJ, Wang X and Cao XC: miR-361-5p suppresses lung cancer cell lines progression by targeting FOXM1. Neoplasma. 64:526–534. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Li P, Wang X, Shan Q, Wu Y and Wang Z: MicroRNA-130b promotes cell migration and invasion by inhibiting peroxisome proliferator-activated receptor-γ in human glioma. Oncol Lett. 13:2615–2622. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Rothschild SI, Tschan MP, Jaggi R, Fey MF, Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077. 2012. View Article : Google Scholar : PubMed/NCBI

30 

He X, Wei Y, Wang Y, Liu L, Wang W and Li N: miR-381 functions as a tumor suppressor in colorectal cancer by targeting Twist1. Onco Targets Ther. 9:1231–1239. 2016.PubMed/NCBI

31 

Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017. View Article : Google Scholar : PubMed/NCBI

32 

Zhang Q, Zhao S, Pang X and Chi B: MicroRNA-381 suppresses cell growth and invasion by targeting the liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep. 35:1831–1840. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Ming J, Zhou Y, Du J, Fan S, Pan B, Wang Y, Fan L and Jiang J: miR-381 suppresses C/EBPα-dependent Cx43 expression in breast cancer cells. Biosci Rep. 35:e002662015. View Article : Google Scholar : PubMed/NCBI

34 

Li Y, Zhao C, Yu Z, Chen J, She X, Li P, Liu C, Zhang Y, Feng J, Fu H, et al: Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. Oncotarget. 7:68585–68596. 2016.PubMed/NCBI

35 

Chen B, Duan L, Yin G, Tan J and Jiang X: miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Liang Y, Zhao Q, Fan L, Zhang Z, Tan B, Liu Y and Li Y: Down-regulation of microRNA-381 promotes cell proliferation and invasion in colon cancer through up-regulation of LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI

37 

Xue Y, Xu W, Zhao W, Wang W, Zhang D and Wu P: miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. Biomed Pharmacother. 86:426–433. 2017. View Article : Google Scholar : PubMed/NCBI

38 

Wang Z, Yang J, Xu G, Wang W, Liu C, Yang H, Yu Z, Lei Q, Xiao L, Xiong J, et al: Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Oncotarget. 6:3147–3164. 2015.PubMed/NCBI

39 

Tang H, Wang Z, Liu Q, Liu X, Wu M and Li G: Disturbing miR-182 and −381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014. View Article : Google Scholar : PubMed/NCBI

40 

Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Chen B and Liu B: miRNA-381 inhibits the invasion of renal carcinoma and the underlying mechanisms. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 40:1053–1059. 2015.PubMed/NCBI

42 

LeRoith D and Helman L: The new kid on the block (ade) of the IGF-1 receptor. Cancer Cell. 5:201–202. 2004. View Article : Google Scholar : PubMed/NCBI

43 

Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008. View Article : Google Scholar : PubMed/NCBI

44 

E C, Li J, Shao D, Zhang D, Pan Y, Chen L and Zhang X: The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway. Oncol Res. 21:103–110. 2013.PubMed/NCBI

45 

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY and Kim TJ: Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Lung Cancer. 87:311–317. 2015. View Article : Google Scholar : PubMed/NCBI

46 

Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J, Hu S and Xiao W: Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett. 317:150–156. 2012. View Article : Google Scholar : PubMed/NCBI

47 

Gryko M, Kisluk J, Cepowicz D, Zińczuk J, Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona A and Kędra B: Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol. 65:135–140. 2014. View Article : Google Scholar : PubMed/NCBI

48 

Shan HB, Zhang R, Li Y, Xu GL, Luo GY, Gao XY and Yang HL: Expression of IGF-1R in colorectal polyps and its role in colorectal carcinogenesis. Technol Cancer Res Treat. 10:381–389. 2011. View Article : Google Scholar : PubMed/NCBI

49 

Xie QX, Lin XC, Zhang MF, Han CX and Guo YH: Expression of IGF-I and IGF-IR in bladder cancer. Ai Zheng. 23:707–709. 2004.(In Chinese). PubMed/NCBI

50 

Werner H and LeRoith D: The role of the insulin-like growth factor system in human cancer. Adv Cancer Res. 68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI

51 

Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI

52 

King H, Aleksic T, Haluska P and Macaulay VM: Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI

53 

Pavelić J, Radaković B and Pavelić K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol. 105:727–735. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2018
Volume 17 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tu, C., Wang, F., & Wan, J. (2018). MicroRNA-381 inhibits cell proliferation and invasion in endometrial carcinoma by targeting the IGF-1R. Molecular Medicine Reports, 17, 4090-4098. https://doi.org/10.3892/mmr.2017.8288
MLA
Tu, C., Wang, F., Wan, J."MicroRNA-381 inhibits cell proliferation and invasion in endometrial carcinoma by targeting the IGF-1R". Molecular Medicine Reports 17.3 (2018): 4090-4098.
Chicago
Tu, C., Wang, F., Wan, J."MicroRNA-381 inhibits cell proliferation and invasion in endometrial carcinoma by targeting the IGF-1R". Molecular Medicine Reports 17, no. 3 (2018): 4090-4098. https://doi.org/10.3892/mmr.2017.8288